Research ArticleOncology
Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
Karolien E. Goffin, Steven Joniau, Peter Tenke, Kevin Slawin, Eric A. Klein, Nancy Stambler, Thomas Strack, John Babich, Thomas Armor and Vivien Wong
Journal of Nuclear Medicine September 2017, 58 (9) 1408-1413; DOI: https://doi.org/10.2967/jnumed.116.187807
Karolien E. Goffin
1Nuclear Medicine, UZ Leuven, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
Steven Joniau
2Urology, UZ Leuven, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
Peter Tenke
3Jahn Ferenc South Pest Hospital, Budapest, Hungary
Kevin Slawin
4University of Texas Vanguard Urologic Institute, Houston, Texas
Eric A. Klein
5Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio
Nancy Stambler
6Progenics Pharmaceuticals, New York, New York; and
Thomas Strack
6Progenics Pharmaceuticals, New York, New York; and
John Babich
7Weill Cornell Medicine, New York, New York
Thomas Armor
6Progenics Pharmaceuticals, New York, New York; and
Vivien Wong
6Progenics Pharmaceuticals, New York, New York; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 9
September 1, 2017
Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
Karolien E. Goffin, Steven Joniau, Peter Tenke, Kevin Slawin, Eric A. Klein, Nancy Stambler, Thomas Strack, John Babich, Thomas Armor, Vivien Wong
Journal of Nuclear Medicine Sep 2017, 58 (9) 1408-1413; DOI: 10.2967/jnumed.116.187807
Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
Karolien E. Goffin, Steven Joniau, Peter Tenke, Kevin Slawin, Eric A. Klein, Nancy Stambler, Thomas Strack, John Babich, Thomas Armor, Vivien Wong
Journal of Nuclear Medicine Sep 2017, 58 (9) 1408-1413; DOI: 10.2967/jnumed.116.187807
Jump to section
Related Articles
Cited By...
- Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer
- Feasibility of 99mTc-MIP-1404 for SPECT/CT Imaging and Subsequent PSMA-Radioguided Surgery in Early Biochemically Recurrent Prostate Cancer: A Case Series of 9 Patients
- SPECT/CT: Standing on the Shoulders of Giants, It Is Time to Reach for the Sky!
- Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer
- Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study